IDH1 and acute myeloid leukemia: Promisingly, a novel, selective IDH1 inhibitor, Olutasidenib, used as a single agent or in combination with 5-azacytidine, has induced a deep clinical response in IDH1 mutated AML patients in phase I clinical trial [74].